13F Holdings
中文EN

PMVP PMV Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1699382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.0%
TTM EPS YoY1.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.4%
ROA-72.2%
ROIC (approx.)-100.2%
Asset turnover—

Leverage & solvency

Liabilities / assets48.7%
Debt / equity0.00x
Current ratio9.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$69.88M$58.53M$55.88M$51.99M$36.49M
SG&A expense$16.33M$26.92M$24.25M$25.05M$21.80M
Operating income-$86.21M-$85.45M-$80.13M-$77.04M-$58.29M
Pretax income-$79.91M-$74.81M-$68.96M-$73.33M-$57.82M
Income tax-$2.17M-$16.10M$2,000-$9,000$23,000
Net income-$77.74M-$58.71M-$68.96M-$73.32M-$57.85M
EBITDA-$86.07M-$84.30M-$78.88M-$76.72M-$57.99M
EPS (basic)-1.48-1.14-1.44-1.61-1.28
EPS (diluted)-1.48-1.14-1.44-1.61-1.28
Weighted avg. shares (diluted)52.54M51.58M48.01M45.59M45.14M
Banking
Net interest income$6.34M$10.65M$11.17M$3.63M$449,000
Balance sheet
Cash & equivalents$37.98M$40.88M$37.71M$108.30M$172.47M
Short-term investments$74.96M$128.58M$165.35M$132.76M$124.70M
Current assets$115.23M$175.66M$207.41M$247.01M$301.29M
PP&E, net$237,000$409,000$10.67M$10.96M$3.09M
Total assets$116.56M$191.29M$252.15M$270.31M$331.57M
Current liabilities$11.41M$14.37M$14.03M$10.83M$12.22M
Total liabilities$11.85M$15.21M$26.46M$24.28M$23.01M
Shareholders' equity$104.71M$176.08M$225.69M$246.03M$308.56M
Shares outstanding53.33M51.94M51.45M45.77M45.43M
Cash flow statement
Operating cash flow-$73.58M-$51.28M-$55.66M-$63.76M-$46.57M
Capital expenditure$29,000$655,000$962,000$7.98M$1.35M
Free cash flow-$73.61M-$51.94M-$56.62M-$71.74M-$47.92M
Investing cash flow$70.17M$53.35M-$50.55M-$1.37M-$143.58M
Financing cash flow$505,000$313,000$35.58M$958,000$2.02M
Depreciation & amortization$133,000$1.14M$1.26M$315,000$307,000
Stock-based compensation$5.92M$8.87M$12.38M$10.20M$5.34M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.